Holmes FA, Moy B, Delaloge S, Chia SKL, et al. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. Eur J Cancer 2023;184:48-59.
PMID: 36898233